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SUMMARY 
Introduction.  
The Patnaik histological grade is the most commonly used prognostic indicator for canine 
cutaneous mast cell tumours (MCTs). The majority of dogs with high histological grade 
MCTs die from their disease after local therapy alone within a year of diagnosis, whereas 
most dogs with low grade MCTs are cured with appropriate local treatment. The behaviour of 
intermediate MCTs is more difficult to predict because they behave as low grade tumours in 
approximately 75% of cases and as high grade tumours in the remaining 25%.  
The differentiation of intermediate grade MCTs with aggressive behaviour from the more 
benign forms represents a great diagnostic challenge. In the last few years a 2-tier histological 
grading system and the use of markers of cell proliferation such as mitotic index, Ki67 index 
and Minichromosome Maintenance Protein 7 (MCM7) score have been investigated to 
overcome this limitation. In one study, a new 2-tier histological grading system was proven to 
be a better predictor of survival than the Patnaik grading scheme. This new system is 
currently awaiting validation in other studies. Mitotic index and Ki67 index have been 
significantly associated with survival independently from the tumour grade in multiple 
studies. Many diagnostic commercial laboratories routinely offer these prognostic markers to 
differentiate aggressive from non-aggressive intermediate grade MCTs.  
The author investigated a novel proliferation marker called MCM7 as a prognostic marker in 
canine MCTs. MCM7 was found to be completely independent from the histological grade 
and significantly associated with survival. 
Objective. The primary objective of the present study is to validate the MCM7 as a 
prognostic marker in a different cohort of dogs with intermediate grade MCTs. 
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The secondary objective is to compare the ability of the 2-tier histological grading system, 
mitotic index, Ki67 index and MCM7 score to predict survival of canine MCTs. 
Materials and methods.  
This is a retrospective study including samples of dogs with a histological diagnosis of 
intermediate grade cutaneous MCTs and known outcome. Samples were collected from the 
archive of the Diagnostic Laboratory of the Animal Health Trust. Follow up was obtained 
from the laboratory database or the submitting veterinary practice. For each sample the 2-tier 
histological grade, mitotic index, Ki67 index and MCM7 score was determined. Results were 
then analysed with statistical methods to compare the ability of each prognostic marker to 
predict outcome. 
Results.  
Population 
A total of 90 dogs with intermediate grade MCT were included in this study. The median age 
of this cohort of dogs was 7.7 years (range 2 months - 15 years). There were 42 females and 
48 males. Nineteen different breeds were represented with Labrador retriever, Golden 
retriever, and Boxer being approximately 60% of the entire study population. There were 39 
MCTs located in the trunk, 36 in the extremities, 11 tumours in the head, and 4 in an 
unknown cutaneous site. The margin of excision was available in all cases: it was complete in 
31 dogs, with narrow margin in 20 cases (less than 1mm), and infiltrated in the other 39 
patients. 
ROC curve 
A ROC curve was obtained to evaluate the performance in predicting death due to causes 
associated with the MCT for each prognostic marker. The area under the curve (AUC) of the 
MI was 0.78 (95% CI 0.64-0.91), the AUC of Ki67 was 0.89 (95% CI 0.80-0.98) and the 
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AUC of MCM7 was 0.87 (95% CI 0.76-0.98). The ROC curve also confirmed that the 
threshold value chosen for each parameter in previous studies was still appropriate. 
Association between prognostic variables and survival 
Cases with high Kiupel grade overlapped precisely with cases with high mitotic index and 
therefore these two variables were considered the same for the rest of the study. In this section 
only analysis for MI will be reported.  
There were 82 dogs with MI ≤ 5 and 8 dogs with MI > 5; 57 dogs with Ki67 ≤ 0.018 and 23 
with Ki67 > 0.018; 65 dogs with MCM7 ≤ 0.18 and 25 dogs with MCM7 > 0.18. A 
significant association was present between categories of MI, Ki67 and MCM7 and death 
related to the mast cell disease (Fisher’s exact test; P <0.001). 
Survival analysis 
The median survival for the entire population was not reached at 2099 days. The mean 
survival time was 1708 days [95% C.I. 1546-1870]. Seventy-two cases were censored after a 
median follow up of 1136 days [range 491-2099] and 18 dogs died for causes related to the 
mast cell tumour after a median of 116 days [range 3-292].  
Kaplan–Meier survival plots and corresponding log-rank tests for MI, Ki-67 and MCM7 as 
categorical variables were highly significant (P <0.0001). Multivariable Cox proportional 
hazard regression analysis of MI, Ki67 and MCM7 corrected for age and surgical margins 
indicated that the higher risk of dying for causes associated with the mast cell disease was 
associated with MCM7 > 0.18 (HR 14.7; P <0.001) followed by MI > 5 (HR 13.9; P <0.001) 
and Ki67 > 0.018 (HR 8.9; P <0.001). Another multivariable model which included MI, Ki67 
and MCM7 showed that these prognostic marker were independent from each other. 
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Conclusion. The present study confirms that MCM7 is an excellent prognostic marker in 
cutaneous MCTs and is able to divide Patnaik intermediate grade tumours in two categories 
with different prognosis.  
The comparison between different prognostic indicators showed that the mitotic index is a 
good test, but lacks of sensitivity, while Ki67 and MCM7 are both excellent tests with high 
sensitivity and high specificity. In this study, cases with high Kiupel grade overlapped 
entirely with cases with high mitotic index and therefore they were evaluated together. MI, 
Ki67 and MCM7 were independent prognostic markers and therefore it would make sense to 
combine them to improve their individual prognostic value. 
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1.0 INTRODUCTION 
1.1 AETIOLOGY 
Mast cell tumours (MCTs) are the most common cutaneous tumours in dogs, 
accounting for 16-21% of cutaneous tumours [1, 2]. 
The aetiology of MCTs is largely unknown as is the reason of the high incidence 
in dogs. Some studies have investigated a viral aetiology or chronic skin irritation, but 
unequivocal evidence is lacking [3-5]. 
The genetic alterations that predispose to canine MCTs are not completely 
understood. Alteration of the p53 tumour suppressor pathway have been identified in 
some canine MCTs, but p53 sequencing in a limited number of cases has revealed no 
mutations [5]. 
Stem cell factor (SCF) has been shown to be an important growth factor for mast 
cells [3]. Kit is the receptor of SCF and it is encoded by the proto-oncogene c-Kit. 
SCF-Kit interactions are required for the differentiation, survival, and normal function 
of mast cells. Several authors have recently identified the presence of activating 
mutations in the proto-oncogene c-Kit in canine MCTs [6-8]. Mutations appear to be 
more common in intermediate and high grade canine MCTs [9, 10] and consist most 
commonly of internal tandem duplication in the juxtamembrane domain of c-Kit in 
exon 11 and 12 [9-11]. Less frequently mutations can occur in the immunoglobulin-
like domain of c-Kit in exon 8 and exon 9 [8, 11] and rarely in the phosphotransferase 
portion of the c-Kit kinase domain between exon 16 and 20 [12].  
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1.2 SIGNALMENT 
MCTs are primarily a disease of older dogs [13, 14]. No sex predisposition has 
been reported. Many authors report a breed predisposition for Boxers, Labrador 
retrievers, Golden retrievers, Bull terriers, Shar-peis, and Schnauzers [3, 5, 14]. 
 
1.3 CLINICAL PRESENTATION 
The vast majority of MCTs originate in the skin and subcutaneous tissue, but 
tumours arising from other sites have been uncommonly reported. 
Cutaneous MCTs have a wide range of clinical presentation. Some of them have a 
history of shrinking and swelling related to intermittent mast cell degranulation and 
histamine release [4]. They usually appear as alopecic, oedematous, and erythematous 
masses or plaques [15]. 
Approximately 40% of tumours are located on the extremities (limbs and tail), 
40% on the trunk including prepuce, perineum and inguinal region, and 20% on the 
head and neck [16]. Most commonly, dogs are presented with a single tumour, but 
multiple tumours are not uncommon accounting for 9-21% of cases [16, 17]. 
Most patients are evaluated by the veterinary surgeon for a skin mass and are 
otherwise asymptomatic. Clinical signs related with MCTs are associated to the 
biologically active substances contained in the cytoplasmic granules such as 
histamine, heparin, and proteolytic enzymes. Occasionally, mechanical manipulation 
during examination of the tumour results in degranulation and subsequent erythema 
and wheal formation in the surrounding tissues, a phenomenon referred as Darier’s 
sign. Other disorders caused by the release of the granules include gastrointestinal 
ulceration and perforation, hypotensive shock, coagulation abnormalities, and wound 
dehiscence [18]. Gastrointestinal ulceration is common, reported to occur in 35-83% 
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of necropsy specimens [5]. However, the fact that these numbers arose from a 
necropsy population is likely to overstate the prevalence of ulceration in the clinical 
setting. Degranulation of the mast cells secondary to the mechanical stimulation of the 
tumour (even walking if the tumour is located in a digit or an axilla) can lead to 
potentially life-threatening hypotensive events. Coagulation abnormalities are thought 
to be associated with heparin release, but they are clinically significant only in the 
perioperative period as localised haemorrhages [5]. MCTs were thought to cause 
delayed healing and wound dehiscence after removal, but a recent study showed that 
the rate of post- surgical complications of MCTs is not different from other cutaneous 
tumours [19].  
 
1.4 DIAGNOSIS 
MCTs are most commonly diagnosed from a fine-needle aspirate on cytology. 
Mast cells have distinctive discrete round cells characteristics and in addition fine to 
coarse metachromatic cytoplasmic granules (Figure 1 and 2). These granules allow a 
definitive diagnosis in the majority of cases. 
Most practices use for in-house cytology dip stains such as Diff-Quik and Hema3 
which are aqueous Romanowsky stains. These are adequate in the majority of cases, 
but occasionally they can fail to stain the characteristic granules making difficult to 
accurate distinguish a MCTs from other round cell tumours [20]. On such occasions, 
methanolic Romanowsky stains, such as Wright’s and Wright-Giemsa or Toluidine 
blue should be used to reveal cytoplasmic granules. 
After surgical excision histopathology is the gold standard for the diagnosis of 
MCTs (Figure 3 and 4). The major advantages of histology over cytology are that it 
allows grading the tumour, providing essential prognostic information, and also the 
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evaluation of surgical margins. In dogs most neoplastic mast cells resemble their 
normal counterparts making the diagnosis relatively easy. The cells are round with 
round central to slightly eccentric nuclei and moderate, pink cytoplasm containing 
granules which stain light grey/blue with haematoxylin/eosin (HE) or purple with 
metachromatic stains. 
Collagenolysis, sclerosis, oedema, necrosis and secondary inflammation are often 
seen in MCTs, and when severe, they can obscure neoplastic cells and make 
assessment of the surgical margin difficult [15]. 
Histological grading systems have been developed to assist the clinicians in 
determining the outcome of dogs with cutaneous MCTs. The most widely accepted is 
the Patnaik grading system (Table 1) [13]. Recently a new grading scheme has been 
published by Kiupel and colleagues (Table 2) [21]. 
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Table 1.Patnaik grading system for canine mast cell tumours. 
 
 
 
 
 
 
 
 
          Table 2. Kiupel grading system for canine mast cell tumours. 
 
 
 
14 
 
1.5 STAGING 
 
Clinical staging is the determination of the degree of local and systemic 
involvement of a tumour. The World Health Organisation (WHO) has developed 
clinical staging for canine MCTs (Table 3) [22]. 
The true metastatic potential of canine MCTs has not been determined, but there 
are data suggesting that the metastatic potential of well-differentiated MCTs is low 
(<5%), of intermediate grades is low to moderate (5-22%) [14, 23], and of poorly 
differentiated tumours is between 55-96% [5]. Most of these tumours disseminate first 
to the regional lymph node and then to visceral organs, mainly spleen and liver. 
Rarely, neoplastic mast cells might be observed in the peripheral blood and bone 
marrow. Involvement of the lungs is also rare [4, 5]. Routine clinical staging for 
MCTs should include haematology, fine-needle aspiration of the regional lymph node, 
abdominal ultrasound plus or minus fine-needle aspiration of liver and spleen and 
bone marrow aspirate. 
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Table 3. World Health Organisation (WHO) Clinical Staging System  
for Mast Cell Tumours. 
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1.6 PROGNOSTIC FACTORS 
Many prognostic factors have been evaluated in canine MCTs: 
- Histological grade 
The Patnaik histological grade is the most consistent prognostic factor in dogs with 
cutaneous MCTs [5, 13, 14]. Generally, dogs with high grade tumours die of their 
disease after local therapy alone within a year, whereas dogs with low grade tumours 
are generally cured with appropriate local treatment. The behaviour of intermediate 
grade MCTs is more difficult to predict because they behave as low grade tumours in 
75% of cases and as high grade tumour in the remaining 25% [23-25]. The uncertainty 
of the prognosis of intermediate grade MCTs together with the subjectivity of the 
application of the grading scheme [26] is what prompted the development of a new 2-
tier grading scheme published in 2011 [21]. The new scheme divides MCTs in two 
grades depending on morphological criteria and number of mitoses. Validation studies 
for the new system are currently not available, but many commercial laboratories have 
already started to report it in addition to the Patnaik system (Figure 5 and 6). 
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- Clinical stage and substage 
Although the clinical staging scheme has been developed for prognostic 
purposes, each increase in stage (0-IV) has not been necessarily proven to worsen 
the prognosis. In particular dogs with stage III disease (multiple cutaneous 
tumours) have a similar prognosis of dogs with stage I disease (single tumour 
confined to the dermis) after proper surgical management [16, 27]. Dogs with 
stage II  (involvement of the local draining lymph node) have a shorter survival 
than dogs with stage I disease [28]. Finding distant metastases in visceral organs 
[29, 30] or bone marrow [31] carries a guarded prognosis.  
The presence of systemic signs (gastrointestinal signs or collapse) or substage 
b is also considered a negative prognostic indicator [5]. 
 
- Anatomic location 
Tumour in the preputial/inguinal area, subungual region, and other 
mucocutaneous sites, including oral cavity and perineum, are anecdotally 
associated with more aggressive behaviour. However, two recent studies suggested 
no difference in outcome for dogs with inguinal or perineal MCTs compared to 
dogs with tumours in other sites [32, 33]. There is one study suggesting that MCTs 
located in the muzzle are biologically more aggressive with a higher regional 
metastatic rate than previously reported for tumours in other sites [34, 35]. 
The involvement of visceral organs always carries a guarded to poor prognosis 
[36, 37]. 
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- Cutaneous/Subcutaneous location 
MCTs arising from and confined to the subcutaneous tissue have extended 
survival times and disease-free survival and are associated with a low rate of local 
recurrence and metastatic rate. Significant negative prognostic indicators include 
mitotic index, infiltrative growth pattern and the presence of multinucleation [38].  
The Patnaik or Kiupel grading scheme should not be applied to this subset of 
MCTs. 
 
- Cell proliferation rate 
o Mitotic index (MI) is defined as the number of mitoses per 10 high-power 
fields (400X) and can be determined with haematoxylin and eosin stained 
sections. Three recent studies [39-41] found a significant association between 
MI, tumour grade and overall survival.  
o Bromodeoxyuridine (BrDU), an analogue to thymidine, is incorporated in vivo 
in the nucleus in S phase and can be detected by immunohistochemistry on 
formalin-fixed, paraffin embedded tissue. A study showed that BrDU labelling 
index correlates well with the mitotic index and the Ki-67 index [42]. 
o Relative frequency of argyrophilic nucleolar staining organising regions 
(AgNORs) proteins are a set of nuclear proteins that increases gradually from 
early G1 phase, reaches the maximum value at the end of S-phase, and remains 
constant up to the late G2 phase. This stain can be performed on a formalin-
fixed specimen. The relative frequency of AgNOR has been correlated with the 
rate of cell proliferation or doubling time in vitro [43]. In multiple studies it 
has been demonstrated that the relative frequency of AgNOR correlates with 
the histological grade and is predictive of postsurgical outcome [43-45]. In 
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another study the AGNOR score could predict the outcome independently from 
the Patnaik grade [46]. 
o Ki-67 protein is a non-histone nuclear protein present during all active phases 
of the cell cycle (G1, S, G2, and M), but absent in quiescent or resting cells. 
Multiple studies [41, 43, 46, 47] found that Ki-67 protein score was 
significantly associated with survival independently from the tumour grade. 
Moreover Ki-67 score is able to predict survival for intermediate grade tumour 
[25, 41]. 
o Proliferating cell nuclear antigen (PCNA) is a nuclear protein which functions 
as a co-factor for DNA-polymerase delta in both the G phase and DNA 
synthesis. In one study [45] PCNA was considerably higher in recurrent versus 
non-recurrent tumours and in metastatic versus non-metastatic tumours. In the 
same study it was a good predictor for tumour recurrence at 6 months. 
However, two recent studies [43, 46] found that PCNA score was not 
significantly associated with an increased risk of local recurrence, metastatic 
spread or MCT-related death. 
o Minichromosome Maintenance Proteins (MCM) are six proteins (MCM2 to 
MCM7) essential for DNA replication and they are thought to function as 
licensing component for the S-phase of the cell cycle initiation [48]. 
Expression of MCM is seen throughout all phases of the cell cycle and is down 
regulated following exit from the cell cycle into quiescence, differentiation or 
senescence. A recent study [49] have shown that the expression of MCM7 was 
significantly associated with survival and completely independent from the 
histological grade in dogs with cutaneous MCTs. 
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- Kit staining pattern and mutation status 
Mutated c-Kit, mostly internal tandem duplication (ITD), is constitutively 
activated and induces growth factor–independent cell proliferation [6-8]. MCTs 
with ITD have significantly higher Ki67 and AgNOR indices indicating increased 
proliferative activity [43]. mRNA encoding for the Kit receptor is overexpressed in 
canine MCT, but there is no association with intracellular protein localization or 
cDNA mutations [11].  
There is contradicting evidence on the prognostic significance of ITD. Multiple 
studies [9, 10, 50] found that ITDs are more likely to occur in intermediate and 
high grade MCTs, suggesting that the mutation has an impact in the aggressiveness 
of the tumour. However, only one study [50] could demonstrate statistically that  
the presence of ITD was significantly associated with decreased survival time, 
increased mortality related to mast cell disease, decreased disease-free interval and 
increased recurrence rate. Expression of the mRNA encoding for the KIT receptor 
and the stem cell factor (SCF) does not appear to be associated with the prognosis 
[11, 51]. 
The vast majority of MCTs express Kit. In normal mast cells and in some 
MCTs Kit appears localized on the cell membrane, while in most MCTs it 
accumulates in the cytoplasm. In the first study, well-differentiated MCTs showed 
a weak expression of Kit, while poorly-differentiated MCTs presented high 
expression [52]. Two subsequent studies [53, 54] identified in MCTs three Kit 
staining patterns: membranous, cytoplasmic focal/stippled and cytoplasmic 
diffuse.  The Kit expression pattern was significantly correlated with histological 
grade, cell differentiation and nuclear grade in one study, but the number of dogs 
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was probably too small for a meaningful evaluation of its prognostic value [53]. 
The other study [54] had a larger population of dogs and identified that the Kit-
staining pattern was associated with local recurrence, death due to MCT, and death 
due to other causes on a multivariable survival analysis. Possible explanations for 
the prognostic value of the c-kit staining pattern is the significant association 
between Kit aberrant intracellular localization and ITD [50, 51] and also between 
Kit aberrant intracellular localization and increased proliferative indices such as 
Ki67 and AgNOR [43]. Two more recent studies [11, 51] did not find a significant 
association between Kit pattern and histological grade, local recurrence or overall 
survival time, but the different IHC method used in these studies or perhaps the 
unavoidable subjectivity in the interpretation can in part explain these 
contradicting results. 
 
1.7 TREATMENT 
Treatment options for MCTs include surgery, radiotherapy and chemotherapy, or a 
combination of these modalities depending on the site of the lesion and the previously 
discussed prognostic factors. 
In general wide surgical excision of the tumour is  the treatment of choice after 
cytological diagnosis if the tumour is in a location amenable to surgery and no 
negative prognostic indicators are present (peritumoral oedema or bruising, lymph 
node or distant metastasis, or presence of systemic signs). Once excised, the tumour is 
sent for grading and histopathologic evaluation of the margins of excision in order to 
decide if further evaluation of prognostic markers, staging or treatment is advisable.  
When the tumour is not amenable to surgical resection or has already metastasised, 
neoadjuvant or palliative chemotherapy is indicated before or instead of surgery [4, 5]. 
 
 
23 
 
Radiotherapy is used to improve local control when surgical margins are infiltrated 
and the location does not allow a second surgery with wider margins [3, 5]. 
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2.0  PREVIOUS WORK ON MAST CELL TUMOUR 
PERFORMED AT THE AHT 
The Animal Health Trust (AHT) has worked on MCTs for the last 10 years.  
At first Sue Murphy performed a retrospective epidemiological study on the 
relationships between the histological grade of cutaneous MCTs in dogs, their survival 
and the efficacy of surgical resection [14]. The study included 280 dogs and found that the 
one-year survival rates for the dogs with MCTs were significantly associated with the 
Patnaik grade, being 100% for grade I, 92% for grade II and 46% for grade III. The 
median survival time for the dogs with poorly differentiated tumours was 278 days, 
significantly shorter than that for the dogs with either intermediately or well-differentiated 
tumours, which were both over 1300 days. Regrowth of the tumours was identified in 10 
(19%) of the dogs with poorly differentiated tumours, 12 (6%) of the dogs with 
intermediately differentiated tumours and one of the dogs with well-differentiated 
tumours; only 3 of the tumours which regrew initially had complete margins.  
A second study looked at the effects of stage and number of tumours on prognosis of 
dogs with cutaneous MCTs [16]. Follow-up data for survival analysis of 145 dogs with 
single tumours and 50 dogs with multiple tumours were evaluated and there was no 
significant difference between the survival times of the two groups. The survival rates 
after 12 and 24 months were 88% and 83%, respectively, for the dogs with single 
tumours, and 86% at both intervals for the dogs with multiple tumours. Eight of the dogs 
with single tumours had lymph node metastases (stage II disease) and these dogs had a 
median survival time of 431 days, whereas the 50 dogs with multiple tumours (classified 
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as stage III disease) and the dogs with single tumours (classified as stage I disease) had 
not reached their median survival times.  
From these studies it appeared that the Patnaik histologic grade was the most 
important prognostic factor, but the clinical progression and behaviour of grade II MCTs 
was still difficult to predict. Hence, the subsequent work focused on the correlation of 
proliferation markers with prognosis [46]. Immunohistochemical staining for Ki67, 
proliferating cell nuclear antigen (PCNA) and a standardized argyrophilic staining of 
nucleolar organizer regions (AgNOR) protocol were performed on 121 archived paraffin-
embedded specimens of canine cutaneous MCTs, for which clinical follow-up data were 
available. Cox regression models indicated that the Ki67 index (HR, 1.92; P < .001) and 
mean AgNOR score (HR, 2.57; P < .001) were significantly associated with Patnaik grade 
and survival time. A binary Ki67 variable with a threshold of 0.018 was a significant 
predictor of survival for dogs with grade II MCTs. The estimated 1-, 2-, and 3-year 
survival probabilities for dogs with grade II MCTs and Ki67 index ≤ 0.018 were 0.92, 
0.86, and 0.77, respectively. The corresponding survival probabilities for dogs with grade 
II MCTs and Ki67 scores > 0.018 were 0.43, 0.21, and 0.21, respectively. No significant 
association was identified between survival and PCNA score. These findings showed that 
both mean AgNOR score and Ki67 index are prognostic markers for canine MCTs, but 
only Ki-67 index could be used to divide Patnaik grade II MCTs into 2 groups with 
markedly different expected survival times. 
A validation study evaluated the association of Ki67 index with prognosis for grade II 
cutaneous MCTs [25]. Ki67 index as a binary variable with a threshold value of 0.018 was 
confirmed to be associated with prognosis (HR, 19.1; P < 0.0001) for this cohort of dogs. 
The 1-year, 2-year and 3-year survival probabilities of 127 dogs with a Ki67 index ≤ 
 
 
26 
 
0.018 were 95%, similar for all, and for 36 dogs with a Ki67 index > 0.018 were 0.54, 
0.45 and 0.33, respectively. 
Another study compared the relative abilities of Ki67 and mitotic index to predict 
survival in dogs with cutaneous MCTs [41]. Histological grade, mitotic index and Ki67 
index were performed in 95 dogs with known outcome. Survival times varied significantly 
between categories of histological grade, mitotic index and Ki67 index. Multivariable 
analyses showed that the risk of dying due to MCT was similar in dogs with increased 
Ki67 index [HR, 3.0 (95% CI 1.3–6.8)] or increased mitotic index [HR, 2.7 (95% CI 1.1–
6.5)]. In conclusion the study showed that both mitotic index and Ki67 index were able to 
independently differentiate MCTs with worse prognosis.  
 Finally, we investigated the value of a novel proliferation marker called 
minichromosome maintenance protein 7 (MCM7) in the prognosis of MCTs [49]. Ninety-
five dogs were included with 31 dying of MCTs. A value of 0.18 was used as threshold 
value of MCM7 score as a binary variable. The median survival time for MCM7 score ≤ 
0.18 was not reached at 3668 days, whereas for MCM7 score > 0.18 was 187 days (log-
rank test; P < 0.0001). In the multivariable analysis, MCM7 was significantly associated 
with survival after controlling for age, surgical margins and histological grade (hazard 
ratio 9.2; P = 0.001). 
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3.0 AIMS AND OBJECTIVES 
3.1  AIMS 
The primary aim of this study was to evaluate the prognostic value of MCM7 
in a different cohort of dogs with intermediate grade MCT. 
The secondary aim was to evaluate the performances of other prognostic 
markers including Kiupel histological grade, mitotic index and Ki67 index. 
 
3.2 OBJECTIVES 
To identify between 100 and 120 samples of dogs with a diagnosis of 
intermediate grade mast cell tumour and known outcome.  
To perform MCM7 score, Kiupel histological grade, mitotic index and 
Ki67 index for each sample blinded to outcome. 
To compare the association between different prognostic factors and 
outcome. 
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4.0  MATERIALS AND METHODS 
4.1 DATA ACCUMULATION 
The AHT is a veterinary charity dedicated to improving the health and welfare of 
dogs, cats, and horses through clinical services and research. Clinical services of the 
AHT are divided into the Centre of Small Animal Studies, the Centre of Equine 
Studies and a Diagnostic Laboratory which offers a service of clinical pathology, 
histopathology, and immunohistochemistry open to any veterinary practice in the 
United Kingdom. 
 A retrospective study was performed to identify dogs bearing MCTs treated 
with surgery alone with known outcome with a target number between 100 and 120 
samples of MCTs. 
 The database of the Diagnostic Laboratory was searched from the years 1997-
2007. The search included all reports containing the words ‘mast cell tumour’.  
Every report was individually reviewed. Reports were discarded if: 
o Belonging to any of other species than canine. 
o It was a cytology examination or immunohistochemical analysis. 
o The final diagnosis was not consistent with MCT. 
o The MCT was located in any other area but the skin (subcutaneous tissue, 
visceral, etc.). 
o The MCT was Patnaik grade I or III. 
o The MCT was a recurrent tumour. 
o The MCT was submitted with a sample of another malignant tumour. 
From each of the remaining reports the following details were entered onto a 
database (Excel, Microsoft, 2010): 
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o Histopathology number 
o Submitting veterinary practice 
o Breed 
o Sex 
o Date of birth 
o Date of submission of the sample 
o Name of the dog 
o Name of the owner 
o Location of the tumour 
o Grade 
o Single or multiple tumour(s) 
o Margin of excision 
Once entered in the database it was possible to sort these data easily, making easier to 
group them depending on the desired characteristic.  
 
4.2 FOLLOW UP 
The follow up of dogs entered in the study was obtained using the database of 
the Diagnostic Laboratory or, alternatively, calling the veterinary surgeon that sent the 
sample to the laboratory or the owner if the dog was a client of the Centre for Small 
Animal Studies of the Animal Health Trust. 
 
4.3 CENSORING OF DATA 
4.3.1 TIME RESTRICTIONS 
A minimal of one year follow up was required for samples of dogs that 
were censored at the survival analysis (alive at the last follow up available or 
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dead for causes not related to the MCT). Events were selected from dogs that 
died from causes related to the MCT within one year from the diagnosis. 
 
4.3.2 TREATMENT 
Treatment can alter greatly the outcome of patients. Therefore, only 
patients treated with surgery and steroids were allowed in the study. Dogs that 
received any other treatment (neoadjuvant or adjuvant chemotherapy or 
adjuvant radiotherapy) were excluded. 
 
4.4 SURVIVAL DATA 
The date of diagnosis, as the day of submission of the sample to the laboratory, 
was used as entry point. Another possibility would have been using the date the owner 
first noticed the mass, but this was thought inaccurate and extremely variable as it 
relied on the owner’s memory. The last reported date that the patient was seen alive by 
the referring practice or the day that the patient died if it was for causes unrelated to 
the MCT was used as date of censor. Dogs reported as dead due to mast cell tumour 
were recorded as events. This end point was used to generate Kaplan-Meier survival 
plots with associated Log-rank test and for Cox’s regression analyses. As the number 
of events was small we decided not to discriminate between different reasons of death 
due to MCTs.  
 
4.5 MITOTIC INDEX, IMMUNOHISTOCHEMISTRY FOR KI-67 AND MCM7 
Slides were retrieved from the archive of the Diagnostic Laboratory for each 
case that satisfied the inclusion criteria (known outcome, adequate follow up and no 
previous treatment apart from surgery and prednisolone). The slides were then blindly 
reviewed by a single pathologist (Roberta Rasotto, Dip.ECVP) to select the best 
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section for grading (confirm Patnaik and perform Kiupel grade), determination of the 
mitotic index and immunohistochemical analyses.  
 
4.5.1 MITOTIC INDEX 
The mitotic index (MI) was obtained using the same methodology as 
Romansik and colleagues [39] as the aim of the study was to compare different 
prognostic markers as used routinely by diagnostic laboratories. The mitotic 
index (MI) was generated counting the number of mitoses per 10 high-power 
fields (400 X) in the region with the highest overall mitotic activity. A single 
count of 10 HPFs was obtained for each tumour sample. 
 
4.5.2 IMMUNOHISTOCHEMISTRY 
For each paraffin-embedded tissue block two five-micrometer sections 
were obtained and mounted on a positively charged, capillary gap glass slide. 
Antigen retrieval was performed by incubating the mounted section in a 
microwave oven for 10 minutes in an EDTA buffer, pH 9.0 (Dako Cytomation, 
Ely, Cambridgeshire, United Kingdom). Immunohistochemical staining was 
then performed using an automated system (Dako Techmate, Ely, 
Cambridgeshire, United Kingdom). Endogenous peroxidase activity within the 
tissues was then blocked with hydrogen peroxidase, and the sections were then 
incubated for 30 minutes with Ki67 or MCM7 antibody. The Ki67 staining 
(Monoclonal Mouse anti-human, Clone MIB-1, Dako Cytomation, Ely, 
Cambridgeshire, United Kingdom) had already been optimised at a dilution of 
1:400 in a previous study performed at the AHT [46]. The MCM7 staining 
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(Monoclonal Mouse anti-human, Clone CDC47, Neomarkers, Fremont, CA, 
USA) was optimised at a dilution of 1:200.  
The specificity of the MCM7 antibody used in this study was evaluated 
with Western Blot analysis performed on extracts of normal canine skin 
lysates. The antibody was specific and did not appear to cross-react with other 
proteins.  
For both Ki67 and MCM7 immunoreactivity was visualized using a 
two-layer method and chromogen developed with diaminobenzidine. Internal 
positive controls consisted of the normal skin tissues overlying the neoplastic 
proliferations.  For negative controls, the primary antibody was replaced with 
the antibody diluent. 
 
4.5.3 IMAGE CAPTURE AND CELL COUNTING 
The image capture and cell counting were obtained using the same 
procedure of previous studies performed at the AHT [25, 46, 49].  
Each section of Ki67 and MCM7 stain was viewed under light 
microscopy at a magnification of 200X. The expected immunostaining for both 
the antibodies was nuclear. A digital picture of the tumour was obtained. In 
order to avoid necrotic areas often present in the centre of the tumour or 
inflammation at the periphery, the image was captured approximately at one 
third of the distance from the deep and lateral margin.  
The digital picture was then opened with a computer program 
(CellCounter®, 2006), which allowed differential counting of positive and 
negative cells. Positive and negative cell count for each sample was inserted in 
the Excel datasheet which calculated the number of positive cells divided by 
 
 
33 
 
the total number of cell counted generating the Ki67 index (Ki67) and the 
MCM7 score (MCM7). A pathologist (Roberta Rasotto) captured the images, 
while the author (Davide Berlato) performed the cell counts blinded of 
outcome. 
 
4.6 STATISTICAL ANALYSIS 
The ROC curve was used to evaluate the performance of MI, Ki67 and MCM7 
as predictors of MCT-related survival. The test was also used to evaluate whether the 
published threshold value for each parameter was appropriate. 
Preliminary associations between survival measured as a binary outcome and 
predictor variables (measured as categorical variables) were examined using chi-
square analysis or Fishers exact test as appropriate depending on the sample 
distribution.  
Survival periods measured in days up to 2099 from initial presentation were 
used in survival analyses with non-survival defined as death or euthanasia as a 
consequence of the MCT (local recurrence or metastatic disease). Kaplan-Meier 
survival plots and corresponding non-parametric log-rank tests were examined 
initially. Univariable Cox’s proportional hazard regression analysis was also 
performed after checking that the assumption of proportional hazard across categories 
of each variable was not violated. Multivariable Cox’s proportional hazard regression 
analyses were then conducted using a forward stepwise procedure to account for 
potentially significant confounding by age of animals at entry to the study and extent 
of surgical excision. The statistical significance was set at 5%.   
A commercial software was used for the statistical analysis (IBM SPSS 
Statistics 21, Chicago, IL, USA). 
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5.0 RESULTS 
5.1 Study population 
A total of 90 dogs with intermediate grade mast cell tumour were included in this 
study. 
Characteristics of patients are summarized in Table 4. The median age of this 
cohort of dogs was 7.7 years (range from 2.3 months to 15.0 years). There were 42 
females (8 entire and 34 neutered) and 48 males (20 entire and 28 neutered). Nineteen 
different breeds were represented with Labrador retriever, Golden retriever, and Boxer 
being approximately 60% of the entire study population. The location of the tumour 
was assigned to one of four categories (head, trunk, extremities, and unknown). There 
were 39 MCTs located in the trunk, 36 in the extremities, 11 tumours in the head, and 
4 in an unknown cutaneous site. The margin of excision was available in all cases: it 
was complete in 31 dogs, with narrow margin in 20 cases (less than 1mm), and 
infiltrated in the other 39 patients.  
The median survival for the entire population was not reached at 2099 days (Figure 
7). The mean survival time was 1708 days [95% C.I. 1546-1870]. Seventy-two cases 
were censored after a median follow up of 1136 days [range 491-2099] and 18 dogs 
that died for causes related to the mast cell tumour after a median of 116 days [range 
3-292].  
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  Table 4. Signalment and tumour characteristic of the 90 cases included in the study. 
 
 
 
 
 
 
 
36 
 
5.2 Immunohistochemistry 
The Ki67 and MCM-7 antibodies stained in variable proportions the neoplastic 
mast cells and the basal layer of the epidermis in all the samples examined (Figure 8, 
9, 10 and 11). The western blot analysis showed that the anti-human MCM7 antibody 
used for the immunohistochemical analyses  bound only one protein of the expected 
molecular weight (80kDa) confirming its specificity for the canine MCM7 protein 
(Figure 12). 
 
 
37 
 
 
 
 
 
 
38 
 
 
 
 
 
 
39 
 
 
 
 
 
40 
 
5.3 ROC curve for MI, Ki67 and MCM7 
The MI, Ki67 index and MCM7 score was calculated for the 90 samples included 
in the study. A ROC curve for each prognostic indicator was obtained to evaluate the 
performance in predicting death due to causes associated with the MCTs (Figure 13). 
The area under the curve (AUC) of the MI was 0.78 (95% CI 0.64-0.91), the AUC of 
Ki67 was 0.89 (95% CI 0.80-0.98) and the AUC of MCM7 was 0.87 (95% CI 0.76-
0.98). 
The ROC curve also confirmed that the threshold value chosen for each parameter 
in previous studies [39, 46, 49] was appropriate (Table 5). For MI a threshold of 5 was 
associated with a sensitivity of 0.39 and a specificity of 0.99; for Ki67 a threshold of 
0.018 was associated with a sensitivity of 0.78 and a specificity of 0.83; and for 
MCM7 a threshold of 0.18 was associated with a sensitivity of 0.83 and a specificity 
of 0.86. 
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   Table 5. Area under the curve for the ROC curve of MI, Ki67 and MCM7. Sensitivity, speci- 
ficity and accuracy for published threshold values (MI = 5; Ki67 = 0.018; MCM7 = 0.18). 
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5.4 Association between prognostic variables and survival 
Analyses were performed for the Kiupel grade, MI, Ki67 and MCM7.  
Cases with high Kiupel grade overlapped precisely with cases with high mitotic index 
and therefore these two variables were considered the same for the remaining of this 
section and only analysis for MI will be reported.  
There were 82 dogs with MI ≤ 5 and 8 dogs with MI > 5; 57 dogs with Ki67 ≤ 
0.018 and 23 with Ki67 > 0.018; 65 dogs with MCM7 ≤ 0.18 and 25 dogs with MCM7 
> 0.18.  
A significant association was present between categories of MI, Ki67 and MCM7 
and death related to the mast cell disease (Fisher’s exact test; P <0.001). 
 
5.5 Survival analyses 
The survival analysis was performed for the MI, Ki67 and MCM7.  
Kaplan–Meier survival plots and corresponding log-rank tests for MI, Ki-67 and 
MCM7 as categorical variables were highly significant (P <0.0001) (Figure 14 and 
Table 6). 
Univariable Cox proportional hazard regression analysis of individual prognostic 
variables and multivariable Cox proportional hazard regression analysis of each 
individual prognostic variable corrected for age and surgical margins produced similar 
results. All prognostic variables were highly significant (P <0.001) (Table 7). 
A further multivariable Cox proportional hazard regression analysis including all 
predictor variables in the same model after correction for age and surgical margins 
showed that MI, Ki67 and MCM7 were independent variables and maintained their 
significance (Table 8).  
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Figure 14. KM survival plot for MI, Ki67 and MCM7 as a categorical variable. The threshold value for MI was 
5, for Ki67 was 0.018 and for MCM7 was 0.18. 
                     
 
 
 
Table 6. KM survival analyses for MI, Ki67 and MCM7 with median survival time (MST) and survival 
probability at 1-, 2- and 3-year. 
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Table 7. Univariable and multivariable Cox regression analyses for MI, Ki67 and MCM7 with  
Hazard Ratio (HR), 95% Confidence Interval and statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Multivariable Cox regression analysis including MI, Ki67 and MCM7 in the same model. 
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6.0 DISCUSSION 
6.1 Descriptive result 
The primary aim was to evaluate the prognostic value of MCM7 in a different 
cohort of dogs with intermediate grade MCT. 
In our previous study [49] the area under the ROC curve was 0.92 [95% C.I. 0.85–
0.98] and a threshold for the MCM7 score of 0.18 was associated with a sensitivity of 
81% and a specificity of 86% for detecting death associated with the MCT. The risk of 
dying of MCT in dogs with MCM7 > 0.18 after correction for age and surgical 
margins was 9.2 times higher than in dogs with MCM7 < 0.18.  
In the present study including only intermediate grade MCT, the area under the ROC 
curve was 0.87 (95% CI 0.76-0.98) indicating that the test was good to excellent. The 
threshold of 0.18 was considered adequate and associated with a sensitivity of 83% 
and specificity of 86%.  An increased MCM7 score was associated with an increased 
risk of dying of MCT of 14.7 times after correction for age and surgical margins. 
Other prognostic markers including the Kiupel grading system, mitotic index 
and Ki67 index were also evaluated in the present study.  
Cases with high Kiupel grade overlapped completely with cases with high 
mitotic index. A certain degree of overlapping between these two classifications was 
not unexpected because the MI is an important criterion to assign the Kiupel grade, but 
we thought that other criteria involving nuclear atypia (≥3 multinucleated cells in 
10HPF, ≥3 bizarre nuclei in 10HPF, or karyomegaly) would have allowed the 
inclusion of other cases in high Kiupel grade category. It is possible that a higher 
number of cases would have allowed such differentiation. 
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In previous studies [39, 41], a threshold for the mitotic index of 5 applied to the 
intermediate histologic grade was associated with a sensitivity of 38-60% and a 
specificity of 84-95%. The risk of dying of MCT in dogs with MI > 5 was 15.4 times 
higher than in dogs with MI ≤ 5 in the univariable Cox regression analysis [41].  
In the present study we obtained a sensitivity of 39%, which is comparable with the 
result of the study performed by Romansik and colleagues [39], and a specificity of 
99%. An increased mitotic index was associated with a risk of dying of MCT that was 
14.7 times higher in the univariable analysis and 13.9 times higher in the multivariable 
analysis after correction for age and surgical margins. 
 In previous studies [25, 41] a Ki67 of 0.018 applied to intermediate grade 
MCTs was associated with a sensitivity of 60-79% and a specificity of 86-90%. The 
risk of dying of MCT in dogs with Ki67 > 0.018 was 9.8-19.1 times higher than in 
dogs with Ki67 ≤ 0.018. 
In the present study we obtained similar sensitivity and specificity, respectively 78% 
and 83%. In the univariable analysis an increased Ki67 was associated with an 
increased risk of dying of MCT of 11.0 times and 8.9 times in the multivariable 
analysis after correction for age and surgical margins. 
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6.2 Can we improve the performance of these prognostic markers? 
Our results largely confirms previous studies [25, 39, 41, 46, 49]. The mitotic 
index appeared to be a good test, but lacks of sensitivity, while Ki67 and MCM7 are 
both excellent tests with high sensitivity and high specificity when used to predict 
outcome in intermediate grade MCTs.   
MI, Ki67 and MCM7 were independent from each other in the multivariable Cox 
regression analysis (Table 8) and therefore it would make sense to combine them to 
improve their prognostic value. In this study, the majority of false positive was due to 
falsely increased Ki67 or MCM7, while the majority of false negative was due to a 
mitotic index below the threshold (Table 9). 
The mitotic index is reported routinely by most commercial laboratories because it 
can be done from H&E stain at no additional cost. This test is extremely specific, but 
lack of sensitivity. Adding Ki67 or MCM7 in all cases with a MI ≤ 5 could be 
advantageous, because these tests are more sensitive. From our study Ki67 and MCM7 
are equally good and there is no clear benefit in choosing one over the other.  
Performing both MCM7 and Ki67 together can increase the sensitivity to 94%, but not 
without a significant loss of specificity to 74% for an overall accuracy of only 78%. 
This problem can be solved by increasing the threshold of each parameter which 
would maintain a higher sensitivity without compromising the specificity. Examining 
the distribution of the Ki67 and MCM7 between dogs that have been censored and 
dogs that died as a result of the MCT (Figure 15), it is apparent that the majority of 
false positive cases have a 0.018 < Ki67 ≤ 0.05 and 0.18 < MCM7 ≤ 0.25. Indeed, a 
value of Ki67 of 0.5 and a value of MCM7 of 0.25 are associated with a specificity of 
about 95% in the ROC curve (Figure 13).  
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The test that results from the combination of Ki67 with a threshold of 0.05 and MCM7 
with a threshold of 0.25 presents the best performance providing a sensitivity of 83%, 
a specificity of 93% for an overall diagnostic accuracy of 91%. The resulting Kaplan–
Meier survival plot and log-rank test are highly significant (P <0.0001) and reflecting 
nicely the improvement (Figure 16 and table 10). Similar results are seen in the 
multivariable Cox regression analysis (Table 11) where dogs with an increased 
Ki67/MCM7 test were 28.0 times more at risk of dying of MCT than dogs with a low 
Ki67/MCM7 test. 
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Table 9. Summary of false positive and false negative results and number of prognostic markers involved. 
 
 
 
 
Figure 15. Distribution of Ki67 and MCM7 in dogs that have been censored and dogs that died as a result 
of the MCT. The horizontal bar set for a value of Ki67 of 0.050 and a value of MCM7 of 0.25. 
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Figure 16. KM plot obtained from the combination of Ki67 and MCM7 with the individual threshold set 
respectively at 0.018 and 0.18 in the left and KM plot for threshold set at 0.050 for Ki67 and a value of 
0.25 for MCM7. 
 
                    
 
 
 
 
 
 
 
 
 
 
Table 10. KM survival analyses for the combination of Ki67 and MCM7 with median survival time (MST) 
and survival probability at 1-, 2- and 3-year. 
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Table 11. Multivariable Cox regression analyses for the combination of Ki67 and MCM7 with  
Hazard Ratio (HR), 95% Confidence Interval and statistical significance. 
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6.3 WEAKNESS OF THE STUDY 
6.3.1 DATA ACCUMULATION 
One of the major weaknesses of this study is its retrospective nature. 
Follow up data were obtained directly by the referring practice or by the 
owners. The data might have been incomplete or inaccurate in same cases.  
 
6.3.2 CASE SELECTION AND FOLLOW UP 
In order to reduce confounders and possible artefacts related to 
retrospective nature of the study, several measures were adopted: 
o Only dogs with an adequate follow up were included in the study. 
o Dogs with multiple tumours should have been ideally excluded, but this 
would have had a huge impact in the final number of cases. 
o Only patients treated with surgery and steroids were allowed in the 
study as treatment is a major confounder. 
The drawback of the applications of these measures is that it 
reduced greatly the number of cases available for the study. 
 
6.3.3 SURVIVAL 
One of the problems with studies in veterinary medicine is the 
definition of the entry and of the end point.  
In this study, the date of the first submission of the 
histopathology sample is chosen as entry point as it is easy to retrieve 
and consistent for all patients. Another possibility would have been 
choosing the date in which the owner or the veterinary surgeon first 
noted the lump on the dog, but this would have been extremely 
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subjective and dependant on many variables. For example, some 
owners are more careful in examining their own dog or seek the 
veterinary attention sooner than others; similarly, some veterinary 
surgeons are more proactive in investigating and treating a cutaneous 
mass than others.  
The end point of the study is death related to the MCT. This 
included spontaneous death or euthanasia directly related to local or 
systemic disease.  
As veterinarians, we are very fortunate to be responsible of the 
wellbeing of our patients from the first visit to the end of life. In the 
same way we recommend a diagnostic procedure or a treatment, we 
sometimes advise for the humane demise of our patient. The most 
common reason for euthanasia is the deterioration of the quality of life 
to the point that euthanasia is a kind relief to suffering. However, the 
concept of ‘acceptable’ quality of life varies enormously between 
owners and veterinarians making the decision extremely subjective. 
Moreover, concurrent problems such as systemic diseases (chronic 
renal disease, diabetes mellitus, etc.) or simply the severe osteoarthritis 
seen often in old dogs contribute greatly to the final decision. In such 
occasions the investigator has a dilemma because it is difficult to decide 
whether the mast cell tumour was the reason for euthanasia or not. 
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6.3.4 MITOTIC INDEX, IMMUNOHISTOCHEMISTRY, IMAGE 
CAPTURE, AND CELL COUNTING. 
 
There are some limitations in the laboratory related part of the 
study. 
The Ki-67 and the MCM7 were performed by the author who is 
not a pathologist. However, adequate training was provided by the 
pathologists involved in the study and the best effort was made in order 
to produce reliable data. My opinion is that counting negative and 
positive cells for evaluation of Ki-67 and MCM7 is quite 
straightforward once the staining technique has been set up adequately. 
This aspect can also be considered a further strength of both these tests 
considering a future widespread use in a commercial setting. 
The digital image obtained for each immunohistochemistry stain 
to perform the differential counting was taken following the previously 
described method [25, 46]. The picture was obtained approximately 1/3 
of the distance from the deep and lateral margin to avoid necrotic areas 
often present in the centre of the tumour or inflammation at the 
periphery. However, tumours are not homogeneous by definition and 
there are areas of higher proliferation adjacent to areas of decreased 
proliferation. Therefore, the limitation of such method is that the exact 
site of image capture is completely at discretion of the operator. We 
tried to overcome this problem with a strict blinding process in which 
the person (RR) obtaining the image and assigning a random 
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identification number was different from the person (DB) counting the 
cells. 
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7.0 CONCLUSION 
The present study confirms that MCM7 is an excellent prognostic marker in cutaneous 
MCTs.  The performance of MCM7 expressed as area under the curve in the ROC curve or as 
hazard ratio in the multivariable Cox regression analysis is the same in Patnaik intermediate 
grade MCTs as it is including all three histological grades. This is the main difference with 
Ki67 that is an excellent test when used to divide the Patnaik intermediate grade in two 
categories with different prognosis, but does not perform as well when applied to all three 
histological grades.  
Another interesting finding of this study is that MI, Ki67 and MCM7 are independent 
prognostic markers and therefore it would make sense to combine them to improve their 
individual prognostic value. Unfortunately in this study cases with high Kiupel grade 
overlapped entirely with cases with high mitotic index and therefore we could not evaluate the 
new grading system independently.  
In general, the mitotic index is a good test characterised by very high specificity, but lacks 
of sensitivity in detecting intermediate grade MCT with poor prognosis. Most commercial 
laboratories offer routinely MI and Kiupel histologic grade as it can be performed from HE 
sections at no additional cost. Our results suggest that dogs with increased MI or high Kiupel 
grade have a worse prognosis warranting further staging and probably further treatment.  
For cases with intermediate Patnaik grade, low Kiupel grade and low mitotic index, we 
recommend performing either Ki67, MCM7, or better both. Ki67 or MCM7 are equally good 
and there is no reason to suggest one over the other if they are done individually. However, 
the combination of the two increasing the individual threshold value allows obtaining a better 
test characterised by a very good sensitivity (83%) and an excellent specificity (93%).
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